Ind-Swift Labs Q2 FY27: Revenue Soars 50% to ₹234.89 Cr, PAT Jumps 3.5x
Ind-Swift Laboratories reported a strong Q2 FY27 with revenue up 50.15% to ₹234.89 crore. Operating EBITDA surged 4.95x to ₹42.33 crore, and PAT grew 3.54x to ₹31.03 crore. For H1 FY27, revenue increased 35.79% to ₹420.97 crore, with PAT rising 3.29x to ₹55.47 crore. The company attributes growth to its FDF focus and operational scale-up.
The substantial increase in key financial metrics like revenue and profitability, coupled with margin expansion, is expected to have a significant positive impact on investor sentiment and the company's valuation.
The company reported significant year-on-year growth in revenue, operating EBITDA, and PAT, along with margin expansion, indicating strong financial performance and positive business momentum.
Ind-Swift Laboratories Limited announced its unaudited financial results for the second quarter and half year ended September 30, 2026. The company reported a significant step-up in revenue, profitability, and margins, driven by its transition from an API manufacturer to a Finished Dosage Formulations (FDF) manufacturer and the scale-up of its operations.
For Q2 FY27, standalone operating income rose by 50.15% year-on-year to ₹234.89 crore. Operating EBITDA surged 4.95 times to ₹42.33 crore, with the operating EBITDA margin expanding by 1,256.01 basis points to 18.02%. Profit After Tax (PAT) increased by 3.54 times to ₹31.03 crore, and PAT margin improved by 761.18 basis points to 13.21%.
Sequentially, revenue grew by 26.23% and operating EBITDA by 27.02% over Q1 FY27. For the half year ended September 30, 2027 (H1 FY27), operating income increased by 35.79% to ₹420.97 crore, operating EBITDA rose 4.45 times to ₹75.65 crore, and PAT grew 3.29 times to ₹55.47 crore.
The company highlighted improved operating efficiency, with raw material expenses falling to 45.15% of revenue from 49.38% in Q2 FY26. Profit Before Tax (PBT) rose 3.6 times to ₹40.24 crore, despite a decline in non-operating other income. Finance costs also decreased by 33.83%.
Mr. N.R. Munjal, Chairman of Ind-Swift Laboratories, stated that the results validate the strategic choices made, emphasizing the successful transition to an FDF manufacturer and the resulting operating leverage. The company operates with a net-debt-free balance sheet and is focused on scaling operations further and sustaining profitable growth.
What to do with a filing like this
Ind-Swift Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Ind-Swift Laboratories Limited. Read the original for the full detail.